Focused On-demand Library for Casein kinase II subunit alpha 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q8NEV1

UPID:

CSK23_HUMAN

Alternative names:

Casein kinase II alpha 1 polypeptide pseudogene

Alternative UPACC:

Q8NEV1

Background:

Casein kinase II subunit alpha 3, also known as Casein kinase II alpha 1 polypeptide pseudogene, is identified as a probable catalytic subunit of a constantly active serine/threonine-protein kinase complex. This complex is pivotal in phosphorylating a multitude of substrates with acidic residues adjacent to the phosphorylated serine or threonine. Its role as an amplification-dependent oncogene underscores its significance in promoting cell proliferation and tumorigenesis by suppressing the tumor suppressor protein, PML.

Therapeutic significance:

Understanding the role of Casein kinase II subunit alpha 3 could open doors to potential therapeutic strategies, particularly in the context of lung cancer development and progression. Its critical function in cell proliferation and tumorigenesis highlights its potential as a target for innovative cancer therapies.